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Abstract: 
Osteonecrosis of the jaws (ONJ) is rare complication of bisphosphonates use which was described for the first time by Marx 
in 2004. Bisphosphonates (BP) are stable derived of inorganic pyrophosphate which had an antiresorbant effect in the bone 
making them very useful in bone metastasis, especially with the third generation of bisphosphonates. Many risk and trigger 
factors have been described as predisposing to the development of ONJ. The aim of this work is to show if Docetaxel 
administration can be considered as a predisposing factor to develop ONJ. We report a series of 11 patients treated during 5 
years in the maxillofacial surgery department in HU Habib Bourguiba Sfax – Tunisia for ONJ due to BP use for breast cancer 
bone metastasis. Those patients were divised into two sub-groups: with and without concomitant Docetaxel administration. 
All patients’ data (age and delay of appearance of ONJ, cumulative doses and trigger factors) were collected and analyzed. It 
was found that patients treated with Docetaxel in association to bisphosphonates developed ONJ in earlier age, with a lower 
cumulative doses of zoledronic acid within a shorter delay period. ONJ occurred in these patients even in the absence of 
trigger factor and intrinsic risk factors. 
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Introduction 
Bisphosphonates (BP) are a stable derived of Inorganic Pyrophosphate widely used in medical domain 
due to its antiresoptive proprieties especially in bone metastasis. Its use was addicted with the 
appearance of multiple complications such as osteonecrosis of the jaws. Many studies were realized to 
study its characteristics, its risk factors and its appearance delays. Searching PubMed data base using 
“bisphosphonates+docetaxel+ONJ” had found only five articles. In this five years retrospective study, 
we are trying to find if concomitant Docetaxel administration with BP may affect epidemiological 
characteristics of ONJ. 
Patients and methods 
During five years, all women patients’ data treated for bisphosphonates related osteonecrosis of the 
jaws in our maxillofacial surgery department were noted. The following parameters were collected: age, 
bisphosphonates doses, delay of ONJ appearance, trigger factor. Data analysis and statistic results were 
realized using XLSTAT program. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Clinical presentation of oral ulceration and bone exposure in ONJ due to bisphosphonates in a73 year’s 
old woman. 
Results 
During 5 years, eleven patients were treated in our department of maxillofacial surgery for 
bisphosphonate related osteonecrosis of the jaws (Figure 1). Five of those have a history of 
concomitant Docetaxel administration during bisphosphonates treatment. All our patients were treated 
with zoledronic acid with an intravenous administration. The mean age in our patients when ONJ 
appearance was 63,18 years. It was found that it was lower in patients treated with bisphosphonates in 
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association with Docetaxel: 59 years versus 68,5 years in those treated only with bisphosphonates 
(Student tests’ p-value = 0,0013 with an alpha equal to 0,05). Cumulative doses of zoledronic acid were 
about 70,36 mg in average for all patients (40 to 104 mg). They were more important to lead to the 
development of ONJ in patients treated with bisphosphonates only: 86 mg versus 59,5 mg in those 
treated by both molecules (p = 0,0196). 
The delay of appearance of ONJ after the beginning of bisphosphonates treatment was about 24,81 
months in average. It was shorter in patients treated with concomitant administration of 
bisphosphonates and Docetaxel (22,5 months in average) than those treated only with bisphosphonates 
(31 months) (p = 0,0251). It was found that ONJ appeared in 2 cases (40%) even in the absence of 
triggers factors in the first patients group. However, in the second group, a trigger factor was always 
present.  
In this study, we found that patients treated with bisphosphonates in association to Docetaxel 
developed ONJ in earlier age, with a lower cumulative doses of zoledronic acid within a shorter delay 
period. ONJ occurred in these patients even in the absence of trigger factor and intrinsic risk factors. 
The following table contains the summary of our patients’ observations (Table 1): 
 
Table 1 All observations’ data (* Patients treated with concomitant BP and TXT administration, ** Patients treated with BP 
only). 
 
 Age 
(years) 
BP Cumulative 
doses (mg) 
ONJ Apparition delay 
(months) 
Associated risk 
factors 
Trigger factor 
Case 1* 48 44 14 None Tooth extraction 
Case 2* 49 40 10 None None 
Case 3* 58 40 31 Obesity Tooth extraction 
Case 4* 73 95 32 Diabetes None 
Case 5* 56 63 17 Diabetes Infection 
Case 6** 66 100 29 Diabetes 
Obesity 
Tooth extraction 
Case 7** 76 72 34 Diabetes 
Obesity 
Infection 
Case 8** 83 92 24 Diabetes 
Obesity 
Tooth extraction 
Case 9** 56 104 43 None Infection 
Case 10** 59 76 23 Obesity Tooth extraction 
Case 11** 71 48 17 None Tooth extraction 
Discussion 
Bisphosphonates related osteonecrosis of the jaws can be defined by the association of 4 elements: an 
ulcer of the oral mucosa persistent for more than 8 weeks in patients treated with bisphosphonates who 
don’t have a history of facial radiotherapy and no maxillary bone metastasis [1]. Its prevalence seems 
to be difficult to assess [2]. It differ according to the prescribed molecule, its administration route, the 
dosage and the total administration period. Woo and col. revealed that ONJ prevalence vary from 6 to 
10% in patients treated for malignant tumors with intravenous bisphosphonates [3]. It was also 
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described after oral route bisphosphonates with lower rates (from 1case/20000 patients to 
1case/110000 patients per year of bisphosphonates treatment) [4]. Aragon-Ching and col. showed a 
relatively high incidence of occurrence of ONJ in patients with metastatic prostate tumors treated with 
zoledronic acid in association with Docetaxel compared with patients who received only zoledronic 
acid [5]. 
Generally, ONJ affects both sexes. However, its occurrence is more frequent in females [6, 7]. It 
primarily affects the elderly population with reduced capacity of bone turnover. In literature, median 
age was about sixty years (Table 2): 
 
Table 2 Literature review of median age for ONJ appearance 
 
Author Year Patients Median age Extremes 
Merigo [8] 2006 29 69 years 45 – 83 years 
Kos [9] 2010 34 65 years 42 - 80 years 
Pichardo [10] 2013 51 66 years 45 – 84 years 
 
The risk to develop ONJ is more important with zoledronic acid than other molecules (pamidronic, 
alendronic, risedronic and ibandronic acid) and this is due to his very important antiresorbant capacity 
[11, 12].  
The cumulative dose is the total dose of bisphosphonates administered to the patient before the onset of 
ONJ. It is probably the most important predisposing factor for the occurrence and development of this 
complication. A prospective study by Bamias et al. [13] evaluated this relationship: it clearly showed 
that the impact of ONJ was correlated with the cumulative dose of bisphosphonates: the higher 
cumulative dose was, the greater the risk of appearance of ONJ increases. 
According to Woo et al. study in 2006 [3], ONJ had occurred four months on average after the end 
of treatment with BP, with a range from 22 to 39 months. However, it may appear in varying timescales 
ranging from one month to several years[6, 14]. A study conducted in 2012 by Miyazaki et al. of 111 
patients treated with both zoledronic acid and Docetaxel found that 8.1% of patients developed ONJ 
within a shorter delay (14.5 months in average)[15].  
Other risk factors have been described as predisposing to ONJ such as diabetes (a study conducted 
between 2004 and 2006 found that 58% of patients suffered from ONJ were diabetics against 14% of 
diabetics in the general population) [16]. Obesity has also been associated with the risk of ONJ in 
Wessel et al. study [17].  
Tooth extraction was reported as the most important trigger factor in more than half the cases of ONJ 
[18]. Other trigger factors can be found with variable frequencies such as a local infectious episode 
[19] or an oral surgery [20]. Note that ONJ can occur spontaneously [10, 21]. 
Conclusion 
Bisphosphonates related osteonecrosis of the jaws may occur earlier in patients treated with 
bisphosphonates in association with Docetaxel, with lower cumulative doses even in the absence of 
trigger factor and intrinsic risk factors. Larger series will be needed to establish a more significant 
relationship.  
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